We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers.
- Authors
Salvagno, Gian Luca; Henry, Brandon M.; Pighi, Laura; De Nitto, Simone; Lippi, Giuseppe
- Abstract
Objectives: We investigated here the response of anti-SARS-CoV-2 IgA antibodies to BNT162b2 primary vaccination followed by administration of a homologous booster dose in baseline seronegative healthcare workers. Methods: The study population included 69 healthy recipients of primary BNT162b2 vaccination (two doses) followed by administration of a single homologous booster after 8 months. Blood samples were collected throughout the study, starting before the first vaccine dose, up to 1 month after the booster. The serum levels of anti-SARS-CoV-2 IgA were assayed with Euroimmun Anti-SARS-CoV-2 spike S1 ELISA IgA. Results: A first peak of serum anti-SARS-CoV-2 IgA was seen 1 month after the second BNT162b2 dose, after which values gradually declined, with stabilization after 6months. The BNT162b2 booster (third dose) elicited a second peak, comparable to that observed 1 month after the second dose (p=0.100). Highly significant correlationwas found between pre- and post-booster anti-SARS-CoV-2 IgA serum values (r=0.41; p<0.001), whilst no significant correlation was observed with age (r=0.10; p=0.416) or sex (r=0.04; p=0.729). The rate of SARS-CoV-2 IgA seropositive recipients increased from 0% before vaccination to 80 and 97% after the first and second vaccine dose, but then declined becoming 74% at 3 months and 54% at 6 months, respectively, after which stabilization was reached. The BNT162b2 booster dose restored the seropositivity rate to 99%. Conclusions: These results support the suggestion that vaccine boosters may be advisable after 3 months from primary vaccination to restore IgA to protective levels, especially in those at higher risk of SARS-CoV-2 infection and complications.
- Subjects
SARS-CoV-2; IMMUNOGLOBULIN A; HEALTH of medical personnel; COVID-19 vaccines; BOOSTER vaccines; DRUG efficacy
- Publication
Advances in Laboratory Medicine / Avances en Medicina de Laboratorio, 2022, Vol 3, Issue 2, p167
- ISSN
2628-491X
- Publication type
Article
- DOI
10.1515/almed-2022-0033